Imugene Receives Orphan Drug Designation for VAXINIA
Filed with ASX · · 3 pages · English
Story so far
Earlier from Imugene
- Three Complete Responses in Azer-Cel Phase 1b Trial
- First patient dosed in Phase 1 bile tract cancer trial
- Imugene onCARlytics Doses First Patient in IV Combination
- Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million
- Imugene and Kincell Bio Announce Strategic Partnership
Later from Imugene
- Complete Response in MAST Study Maintained Over Two Years
- Imugene Opens First Australian Site for azer-cel Trial
- onCARlytics Trial Doses First Patient in IT Combination Arm
- Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund
- Issuance of Convertible Notes & Warrants for up to $46m
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene